← Medication guidesField medications · Adult & pediatric guidance · ALS
Ondansetron (Zofran)
Adult oral/IV treatment and the pediatric age-4-and-older ODT pathway.
OCEMS source summary · Updated 2026-09-16
Check before giving
- The adult standing order excludes known or suspected pregnancy.
- Do not let symptom control replace assessment of dehydration, poor perfusion, or an altered level of consciousness.
Use in OCEMS
- For ongoing nausea/vomiting in the applicable condition order. Treat associated airway risk and dehydration as well as symptoms.
- The oral dissolving tablet and IV preparation have different dosing instructions.
Adult / adolescent
| Indication / route | Dose & limits |
|---|
| ODT | 8 mg (two 4 mg tablets) dissolved orally, once, when pregnancy is not known or suspected. |
|---|
| IV | 4 mg IV; may repeat 4 mg once after approximately 3 minutes for continued/recurrent symptoms, when pregnancy is not known or suspected. |
|---|
Pediatric
- SO-P-090: children age 4 and older may receive one 4 mg ODT tablet dissolved orally, as tolerated.
- The cited pediatric nausea standing order does not provide routine IV dosing or an ODT dose below age 4. Do not infer a weight-scaled adult regimen.
Pediatric dose by age / weight
- SO-P-090 applies to ongoing nausea/vomiting. Age, not weight, determines eligibility for this fixed dose.
| Age / weight | Pediatric dose | Route / limit |
|---|
| Younger than 4; any weight | No dose in this pediatric standing order | Do not extrapolate from an adult IV dose |
|---|
| Age 4 and older; any eligible pediatric weight | 4 mg | One ODT tablet dissolved orally as tolerated |
|---|
Preparation & reassessment
- Stock includes 4 mg ODT and 4 mg/2 mL IV preparations. Verify the product and route.
- Keep suction available when needed. Reassess vomiting, airway protection, perfusion, and treatment response; follow the applicable fluid pathway.
Markdown version · Sources & editorial approach